Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.
THE PARADIGM FOR THE TREATMENT OF MONOCLONAL GAMMOPATIES HAS DRAMATICALLY CHANGED: therapeutic options in multiple myeloma (MM) have evolved from the introduction of melphalan and prednisone in the 1960s, high-dose chemotherapy and stem cell transplantation in the late 1980s and 1990s, to the rapid introduction of small novel molecules within the last seven years. Based on the understanding of the complex interaction of the MM cells with the bone marrow microenvironment and the signaling pathways that are dysregulated in this process, a number of novel therapeutic agents are now available. Specifically, three novel agents with a specific-targeted anti-MM activity, have been FDA-approved for the treatment of this disease, namely Bortezomib, thalidomide, and lenalidomide which are now all playing a key role in the treatment of MM. The success of targeted therapy in MM has since led to the development and investigation of more than 30 new compounds in this disease and in other plasma cell dyscrasias such as Waldenström's macroglobulinemia and primary amyloidosis, both in the preclinical settings and as part of clinical trials.
Roccaro
Aldo M
AM
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA;
Ghobrial
Irene M
IM
Blotta
Simona
S
Treon
Steven P
SP
Malagola
Michele
M
Anderson
Kenneth C
KC
Richardson
Paul G
PG
Russo
Domenico
D
Ann Oncol. 2005 Jan;16(1):132-8
15598950
Blood. 2004 Aug 1;104(3):607-18
15090448
Leuk Lymphoma. 2004 Oct;45(10):2047-55
15370249
Semin Oncol. 2001 Dec;28(6):607-12
11740818
Blood. 2006 Nov 15;108(10):3458-64
16840727
Blood. 2007 Jan 15;109(2):492-6
16960148
Blood. 2008 Feb 1;111(3):1654-64
18006697
Haematologica. 2005 Dec;90(12):1655-8
16330439
Ann Oncol. 2007 Aug;18(8):1369-75
17693650
Cancer Res. 2005 Jul 1;65(13):5898-906
15994968
J Clin Oncol. 2002 Nov 1;20(21):4319-23
12409330
Eur J Cancer. 2006 Jul;42(11):1612-22
16750621
Blood. 2003 Apr 15;101(8):3126-35
12515720
J Clin Oncol. 2003 Jan 1;21(1):16-9
12506164
Cancer Cell. 2005 Nov;8(5):407-19
16286248
Ann Oncol. 2004 Oct;15(10):1481-3
15367407
Blood. 2006 Nov 15;108(10):3295-301
16873669
Blood. 2007 Jun 1;109(11):4964-72
17284528
N Engl J Med. 2003 Jun 26;348(26):2609-17
12826635
Br J Cancer. 2002 Nov 4;87(10):1166-72
12402158
N Engl J Med. 2005 Jun 16;352(24):2487-98
15958804
Neurology. 2006 Mar 14;66(5):742-4
16534115
Blood. 2004 Dec 15;104(13):4188-93
15319277
Haematologica. 2006 Jul;91(7):929-34
16818280
Cancer Res. 2007 Apr 15;67(8):3777-84
17440091
Blood. 2007 Dec 15;110(13):4417-26
17761832
Semin Oncol. 2003 Apr;30(2):265-9
12720150
J Support Oncol. 2003 Sep-Oct;1(3):194-205
15334875
Curr Opin Oncol. 2006 Nov;18(6):598-608
16988581
Blood. 2006 Feb 1;107(3):1092-100
16234364
Oncogene. 2002 Aug 22;21(37):5673-83
12173037
Blood. 2005 Sep 15;106(6):1901-10
15890683
Leuk Lymphoma. 2004 Mar;45(3):591-5
15160923
Blood. 2008 Feb 15;111(4):1805-10
17875806
Blood. 2005 Dec 15;106(13):4050-3
16118317
N Engl J Med. 2006 May 11;354(19):2079-80
16696148
Haematologica. 2006 Nov;91(11):1498-505
17043025
Lancet. 2006 Mar 11;367(9513):825-31
16530576
Blood. 2006 Nov 15;108(10):3289-94
16873668
Blood. 2002 Nov 1;100(9):3063-7
12384400
Blood. 2006 May 15;107(10):4053-62
16418332
Blood. 2001 Jul 1;98(1):210-6
11418482
Blood. 2006 May 1;107(9):3442-6
16410453
Leukemia. 2005 Oct;19(10):1831-4
16121217
Semin Oncol. 2003 Apr;30(2):243-7
12720145
J Clin Oncol. 2006 Jan 20;24(3):431-6
16365178
Clin Lymphoma. 2005 Mar;5(4):282-4
15794866
Haematologica. 2007 Aug;92(8):1149-50
17650451
J Clin Oncol. 2005 Jan 20;23(3):474-81
15659493
Blood. 2008 May 1;111(9):4752-63
18316628
Mayo Clin Proc. 2000 Sep;75(9):897-901
10994824
N Engl J Med. 1999 Nov 18;341(21):1565-71
10564685
J Clin Oncol. 2005 Jun 20;23(18):4089-99
15867202
Br J Haematol. 2004 Oct;127(2):165-72
15461622
Haematologica. 2007 Oct;92(10):1351-8
18024372
Clin Cancer Res. 2006 Nov 15;12(22):6826-35
17121904
Clin Lymphoma. 2004 Dec;5(3):205-7
15636699
Expert Rev Anticancer Ther. 2006 Aug;6(8):1165-73
16925483
Cancer Res. 2002 Sep 1;62(17):5027-34
12208757
Haematologica. 2007 Oct;92(10):1302-7
18024367
Blood. 2002 Jun 15;99(12):4525-30
12036884
Blood. 2006 Oct 1;108(7):2165-72
16772605
Blood. 2007 Feb 15;109(4):1669-77
17023575
Clin Cancer Res. 2008 Mar 15;14(6):1849-58
18347188
Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):21-4
15651173
Blood. 2005 Apr 1;105(7):2949-51
15572585
Oncogene. 2004 Nov 18;23(54):8766-76
15480425
Cancer. 2004 Dec 1;101(11):2593-8
15493038
Blood. 2000 Nov 1;96(9):2943-50
11049970